Sarcomatoid renal cell carcinoma

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Page editor Section editor
Teja Ganta, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Ali Raza Khaki, MD
Stanford University
Palo Alto, CA, USA


Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.

2 regimens on this page
2 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


Metastatic disease, first-line

Doxorubicin & Gemcitabine


Study Dates of enrollment Evidence
Haas et al. 2012 (ECOG 8802) 2004-2007 Phase 2


Supportive therapy

14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)


  1. ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00068393

Gemcitabine & Sunitinib


Study Dates of enrollment Evidence
Michaelson et al. 2015 (MGH 07-212) 2007-2013 Phase 2


Targeted therapy

21-day cycles


  1. MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article PubMed NCT00556049